Navigation Links
Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America

SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will receive a Corporate Achievement Award from the Huntington's Disease Society of America (HDSA), which honors those companies that exemplify leadership in the fight against Huntington's disease and other neurodegenerative diseases. David Hung, M.D., president and chief executive officer of Medivation, will accept the award during the 12th Annual Guthrie Awards Dinner on Thursday, October 16, at the Waldorf Astoria in New York.

"We are honored to be recognized by the HDSA for our efforts to develop a treatment for Huntington's disease. We are committed to bringing Dimebon to market so patients can gain access to a drug that could truly improve how they, and their families, live with this terrible debilitating disease," said Dr. Hung. "We are encouraged by our Phase 2 trial findings, which, we believe, showed Dimebon to be the first investigational drug to demonstrate a significant benefit in any measure of cognitive function in patients with mild-to-moderate Huntington's disease in a well-controlled study."

Medivation is developing Dimebon, an orally available small molecule, to treat patients with mild-to-moderate Huntington's disease. The Company recently announced that it plans to continue further development of the drug with its new development partner Pfizer based on positive results seen in a Phase 2 trial. In addition, Medivation is evaluating Dimebon in a pivotal and confirmatory Phase 3 trial in patients with Alzheimer's disease.

About Huntington's Disease

Huntington's disease is a progressive, neurodegenerative disease that affects 30,000 patients in the U.S., with another 150,000 at risk. It is caused by the death of specific brain cells and is characterized by the gradual development of involuntary muscle movements, progressive deterioration of cognitive processes and memory (dementia), and severe behavioral disturbances.

About HDSA

HDSA is a national non-profit organization dedicated to improving the lives of people with Huntington's disease and their families. HDSA supports research to eradicate Huntington's disease and assists people and families affected by Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at

This press release contains forward-looking statements, including statements regarding future clinical development plans, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q filed August 11, 2008 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
2. Medivation Announces Participation in Upcoming Conferences
3. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
5. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
7. Medivation Announces Senior Management Promotions
8. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
9. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Post Your Comments:
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , ... Annual Healthcare Conference in New York City ... (1:30 p.m. GMT). --> SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> Shire ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):